 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
2 News |  |
- | CART20 / Beijing Biohealthcare
New P1/2 trial: Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma (clinicaltrials.gov) - Nov 16, 2016
P1/2, N=15, Recruiting, Sponsor: Beijing Biohealthcare Biotechnology Co.,Ltd